Scrip
FDA lifts two-year hold from CytRx's experimental ALS drug
03 December 2009
Asher Mullard
Please Login to read the full article.
03 December 2009
Asher Mullard
The US FDA has said that CytRx can resume testing its experimental amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease) drug arimoclomol, nearly two years after a Phase IIb trial was put on hold. The company's share price rose by 8%, to $1.08, on Nasdaq on the news.
"We're extremely...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Acorda/Biogen Idec's Ampyra becomes first US FDA-approved drug to improve walking in MS
- Synosia reports early clinical data for Parkinson's candidate
- Merck Serono's cladribine may become first oral MS drug after positive Phase III results
- US FDA allows Synta to resume development of anticancer elesclomol
COMMENT
Other Informa Comment
EVENTS
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
